Phase IIa Safety and Efficacy Study of SRD174 Cream in Patients With AD-associated Pruritus

Serentis

Status and phase

Completed

Phase 2

Conditions

Pruritus, Atopic Dermatitis

Treatments

Other: vehicle cream

Drug: SRD174 Cream

Study type

Interventional

Funder types

Industry

Identifiers

NCT00838708

P174954201CD

Details and patient eligibility

About

Pruritus is an essential feature for the diagnosis of atopic dermatitis and may play an important part in disease progression. Itching has a significant impact on the quality of life of AD sufferers, in particular night-time itching leading to sleep disturbance and subsequent poor daytime performance.

The objective of this study is to determine whether SRD174 Cream is a safe and effective therapy for moderate to severe pruritus associated with atopic dermatitis.

Enrollment

62 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Males and females aged 18 years and over moderate to severe AD pruritus
Written signed and dated informed consent
Satisfactory medical assessment with no clinically relevant abnormalities

Exclusion criteria

Subject with active and pruritic AD covering a body surface area (BSA) > 20%
Subject with severe AD defined as an IGA score of 4
Subject with current or recurrent skin disease (except AD) that could affect the site of application of action, absorption or disposition of the investigational product, or clinical, laboratory assessments.
Subjects with unstable or uncontrolled medical conditions that could require intensive treatment during the course of the study.
Subject with known or suspected intolerance or hypersensitivity to the Investigational products or any of the stated ingredients.
Subject who has a medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with interpretation of trial results and, in the judgment if the investigator, would make the subject inappropriate for entry into this trial.